BMRN Quote, Financials, Valuation and Earnings

Moderna has a net margin of 24.92% compared to BioMarin Pharmaceutical's net margin of -907.48%. BioMarin Pharmaceutical's return on equity of 9.62% beat Moderna's return on equity of -29.23%.

BioMarin Pharmaceutical has a consensus price target of $95.69, signalling upside risk potential of 64.34%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 44.79%. Given that BioMarin Pharmaceutical has higher upside potential than Moderna, analysts believe BioMarin Pharmaceutical is more attractive than Moderna.

BioMarin Pharmaceutical has a beta of 0.168, which suggesting that the stock is 83.229% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

BioMarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

BioMarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Moderna quarterly revenues of $107M. BioMarin Pharmaceutical's net income of $185.7M is higher than Moderna's net income of -$971M. Notably, BioMarin Pharmaceutical's price-to-earnings ratio is 21.65x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical is 3.90x versus 4.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 24.92% compared to BioMarin Pharmaceutical's net margin of 21.63%. BioMarin Pharmaceutical's return on equity of 9.62% beat Pfizer's return on equity of 8.72%.

BioMarin Pharmaceutical has a consensus price target of $95.69, signalling upside risk potential of 64.34%. On the other hand Pfizer has an analysts' consensus of $29.14 which suggests that it could grow by 14.96%. Given that BioMarin Pharmaceutical has higher upside potential than Pfizer, analysts believe BioMarin Pharmaceutical is more attractive than Pfizer.

BioMarin Pharmaceutical has a beta of 0.168, which suggesting that the stock is 83.229% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

BioMarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. BioMarin Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

BioMarin Pharmaceutical quarterly revenues are $745.1M, which are smaller than Pfizer quarterly revenues of $13.7B. BioMarin Pharmaceutical's net income of $185.7M is lower than Pfizer's net income of $3B. Notably, BioMarin Pharmaceutical's price-to-earnings ratio is 21.65x while Pfizer's PE ratio is 18.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical is 3.90x versus 2.31x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 24.92% compared to BioMarin Pharmaceutical's net margin of -60.08%. BioMarin Pharmaceutical's return on equity of 9.62% beat Sarepta Therapeutics's return on equity of -20.94%.

BioMarin Pharmaceutical has a consensus price target of $95.69, signalling upside risk potential of 64.34%. On the other hand Sarepta Therapeutics has an analysts' consensus of $47.96 which suggests that it could grow by 149.4%. Given that Sarepta Therapeutics has higher upside potential than BioMarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than BioMarin Pharmaceutical.

BioMarin Pharmaceutical has a beta of 0.168, which suggesting that the stock is 83.229% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

BioMarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

BioMarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Sarepta Therapeutics quarterly revenues of $744.9M. BioMarin Pharmaceutical's net income of $185.7M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, BioMarin Pharmaceutical's price-to-earnings ratio is 21.65x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical is 3.90x versus 0.96x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of 24.92% compared to BioMarin Pharmaceutical's net margin of 40.56%. BioMarin Pharmaceutical's return on equity of 9.62% beat United Therapeutics's return on equity of 19.92%.

BioMarin Pharmaceutical has a consensus price target of $95.69, signalling upside risk potential of 64.34%. On the other hand United Therapeutics has an analysts' consensus of $377.01 which suggests that it could grow by 26.65%. Given that BioMarin Pharmaceutical has higher upside potential than United Therapeutics, analysts believe BioMarin Pharmaceutical is more attractive than United Therapeutics.

BioMarin Pharmaceutical has a beta of 0.168, which suggesting that the stock is 83.229% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.629%.

BioMarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

BioMarin Pharmaceutical quarterly revenues are $745.1M, which are smaller than United Therapeutics quarterly revenues of $794.4M. BioMarin Pharmaceutical's net income of $185.7M is lower than United Therapeutics's net income of $322.2M. Notably, BioMarin Pharmaceutical's price-to-earnings ratio is 21.65x while United Therapeutics's PE ratio is 11.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical is 3.90x versus 4.80x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.